<DOC>
	<DOCNO>NCT00299845</DOCNO>
	<brief_summary>Proton pump inhibitor administer child off-label use Japan . The purpose study evaluate effect CYP2C19 genotypes pharmacokinetic /pharmacodynamic profile PPI child . The result provide beneficial information individualize medicine PPI child .</brief_summary>
	<brief_title>Randomized Trial Pharmacogenomics-based Proton Pump Inhibitor Therapy Children</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<criteria>Patients gastroesophageal reflux The patient 's parent guardian give write informed consent include pharmacogenomic analysis The patient willing able give assent participate . Serious hepatic disease , pulmonary disease , renal disease blood disorder Inadequate clinical condition</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>gastroesophageal reflux</keyword>
	<keyword>child</keyword>
	<keyword>lansoprazole</keyword>
	<keyword>cytochrome P450 2C19 ( CYP2C19 )</keyword>
	<keyword>pharmacogenomics</keyword>
	<keyword>genetic polymorphism</keyword>
	<keyword>individualized medicine</keyword>
	<keyword>pharmacokinetics/dynamics</keyword>
</DOC>